Loading AI tools
Gene therapy medication From Wikipedia, the free encyclopedia
Nadofaragene firadenovec, sold under the brand name Adstiladrin, is a gene therapy for the treatment of bladder cancer.[1][3][4] It is a non-replicating (cannot multiply in human cells) adenoviral vector-based gene therapy.[3]
Gene therapy | |
---|---|
Target gene | Interferon alfa-2b |
Clinical data | |
Trade names | Adstiladrin |
Other names | Nadofaragene firadenovec-vncg, Instilidrin, rAd-IFN/Syn3 |
License data | |
Routes of administration | Intravesical |
ATC code | |
Legal status | |
Legal status | |
Identifiers | |
UNII | |
KEGG |
The most common adverse events including laboratory abnormalities, include increased glucose, instillation site discharge, increased triglycerides, fatigue, bladder spasm, micturition urgency, increased creatinine, hematuria, decreased phosphate, chills, dysuria, and pyrexia.[4]
Nadofaragene firadenovec was approved for medical use in the United States in December 2022.[3][4][5]
Nadofaragene firadenovec is indicated for the treatment of adults with high-risk Bacillus Calmette-Guérin (BCG)-unresponsive non-muscle-invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without papillary tumors.[1][3]
The safety and effectiveness of nadofaragene firadenovec was evaluated in a multicenter clinical study (Study CS-003 (NCT02773849)) that included 157 participants with high-risk Bacillus Calmette-Guérin (BCG)-unresponsive non-muscle-invasive bladder cancer, 98 of whom had BCG-unresponsive carcinoma in situ with or without papillary tumors and could be evaluated for response.[3][4] Participants received nadofaragene firadenovec once every three months for up to twelve months, or until unacceptable toxicity to therapy or recurrent high-grade non-muscle-invasive bladder cancer.[3][4] Overall, 51% of enrolled participants using nadofaragene firadenovec therapy achieved a complete response (the disappearance of all signs of cancer as seen on cystoscopy, biopsied tissue, and urine).[3] The median duration of response was 9.7 months.[3] Forty-six percent of responding participants remained in complete response for at least one year.[3] The major efficacy outcome measures were complete response at any time and duration of response.[4] Complete response was defined as negative cystoscopy with applicable transurethral resection of bladder tumor and biopsies and urine cytology.[4] Random bladder biopsies of five sites were conducted in participants remaining in complete response at twelve months.[4]
The US Food and Drug Administration (FDA) granted the application for nadofaragene firadenovec priority review, breakthrough therapy, fast track, and orphan drug designations.[3][4] The FDA granted approval of Adstiladrin to Ferring Pharmaceuticals A/S.[3]
Nadofaragene firadenovec is the international nonproprietary name (INN).[6]
Seamless Wikipedia browsing. On steroids.
Every time you click a link to Wikipedia, Wiktionary or Wikiquote in your browser's search results, it will show the modern Wikiwand interface.
Wikiwand extension is a five stars, simple, with minimum permission required to keep your browsing private, safe and transparent.